NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis $24.05 +0.41 (+1.74%) As of 03:34 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AMPH alerts:Sign Up Key Stats Today's Range$23.49▼$24.3950-Day Range$18.72▼$23.9152-Week Range$16.65▼$29.52Volume237,171 shsAverage Volume513,478 shsMarket Capitalization$1.02 billionP/E Ratio14.28Dividend YieldN/APrice Target$22.50Consensus RatingReduce Company Overview Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications. Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant. Amphastar also develops additional products through internal research and development programs and strategic acquisitions. Founded in 1996, Amphastar is headquartered in Rancho Cucamonga, California. The company serves the U.S. pharmaceutical market and sells certain products internationally. Amphastar is led by Jack Zhang, Ph.D., who serves as president and chief executive officer and has been associated with the company since its founding.AI Generated. May Contain Errors. Read More Amphastar Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreAMPH MarketRank™: Amphastar Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat, and ranked 756th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingReduce Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and 2 sell ratings.Downside RiskAmphastar Pharmaceuticals has a consensus price target of $22.50, representing about 7.3% downside from its current price of $24.26.Amount of Analyst CoverageAmphastar Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.28% Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 5.28% in the coming year, from $2.46 to $2.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 14.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 14.35, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.61.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 4.61. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Amphastar Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.15% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 15.36, which indicates bearish sentiment.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently decreased by 4.66%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.21 News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest7 people have searched for AMPH on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $421,047.00 in company stock.Percentage Held by Insiders29.60% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMPH Stock News HeadlinesAmphastar Pharmaceuticals (NASDAQ:AMPH) Cut to "Buy" at Wall Street ZenSeptember 12, 2026 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Consensus Rating of "Reduce" by AnalystsSeptember 10, 2026 | americanbankingnews.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.September 16 at 1:00 AM | American Alternative (Ad)Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare ConferenceSeptember 1, 2026 | prnewswire.comZacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and ViatrisAugust 31, 2026 | uk.finance.yahoo.comAmphastar (AMPH) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | finance.yahoo.comThe Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings CallAugust 13, 2026 | msn.comAMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive ResultsAugust 11, 2026 | finance.yahoo.comSee More Headlines AMPH Stock Analysis - Frequently Asked Questions How have AMPH shares performed this year? Amphastar Pharmaceuticals' stock was trading at $26.78 on January 1st, 2026. Since then, AMPH stock has decreased by 9.4% and is now trading at $24.26. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings data on Thursday, August, 6th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.29. The firm earned $183.90 million during the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a trailing twelve-month return on equity of 14.98%. Read the conference call transcript. When did Amphastar Pharmaceuticals IPO? Amphastar Pharmaceuticals (AMPH) raised $88 million in an initial public offering on Wednesday, June 25th 2014. The company issued 8,000,000 shares at $10.00-$12.00 per share. Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' top institutional investors include Denali Advisors LLC (0.88%), Bank of New York Mellon Corp (0.53%), Empowered Funds LLC (0.38%) and Bank of America Corp DE (0.32%). Insiders that own company stock include Mary Z Luo, William J Peters, Rong Zhou, Yakob Liawatidewi, Floyd F Petersen, Richard K Prins and Michael A Zasloff. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/06/2026Today9/16/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 AMPH's financial health is in the Green zone, according to TradeSmith. AMPH has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMPH CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,976Year Founded1996Price Target and Rating Average Price Target for Amphastar Pharmaceuticals$22.50 High Price Target$30.00 Low Price Target$20.00 Potential Upside/Downside-6.9%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$1.69 Trailing P/E Ratio14.27 Forward P/E Ratio9.82 P/E Growth4.61Net Income$98.09 million Net Margins10.76% Pretax Margin13.98% Return on Equity14.98% Return on Assets6.96% Debt Debt-to-Equity Ratio0.79 Current Ratio2.40 Quick Ratio1.71 Sales & Book Value Annual Sales$719.89 million Price / Sales1.43 Cash Flow$4.30 per share Price / Cash Flow5.62 Book Value$17.17 per share Price / Book1.41Miscellaneous Outstanding Shares42,540,000Free Float29,947,000Market Cap$1.03 billion OptionableOptionable Beta0.92 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:AMPH) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMPH Stock Alerts